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Abstract
Purpose The adrenomedullin receptor is densely expressed in
the pulmonary vascular endothelium. PulmoBind, an
adrenomedullin receptor ligand, was developed for molecular
diagnosis of pulmonary vascular disease. We evaluated the
safety of PulmoBind SPECT imaging and its capacity to de-
tect pulmonary vascular disease associated with pulmonary
hypertension (PH) in a human phase II study.
Methods Thirty patients with pulmonary arterial hypertension
(PAH, n = 23) or chronic thromboembolic PH (CTEPH, n = 7)
in WHO functional class II (n = 26) or III (n = 4) were com-
pared to 15 healthy controls. Lung SPECT was performed
after injection of 15mCi 99mTc-PulmoBind in supine position.
Qualitative and semi-quantitative analyses of lung uptake
were performed. Reproducibility of repeated testing was eval-
uated in controls after 1 month.
Results PulmoBind injection was well tolerated without any
serious adverse event. Imaging was markedly abnormal in PH
with ∼50% of subjects showing moderate to severe heteroge-
neity of moderate to severe extent. The abnormalities were
unevenly distributed between the right and left lungs as well
as within each lung. Segmental defects compatible with pul-
monary embolism were present in 7/7 subjects with CTEPH
and in 2/23 subjects with PAH. There were no segmental
defects in controls. The PulmoBind activity distribution index,
a parameter indicative of heterogeneity, was elevated in PH
(65% ± 28%) vs. controls (41% ± 13%, p = 0.0003). In the
only subject with vasodilator-responsive idiopathic PAH,
PulmoBind lung SPECT was completely normal. Repeated
testing 1 month later in healthy controls was well tolerated
and showed no significant variability of PulmoBind
distribution.
Conclusions In this phase II study, molecular SPECT imaging
of the pulmonary vascular endothelium using 99mTc-
PulmoBind was safe. PulmoBind showed potential to detect
both pulmonary embolism and abnormalities indicative of
pulmonary vascular disease in PAH. Phase III studies with this
novel tracer and direct comparisons to lung perfusion agents
such as labeled macro-aggregates of albumin are needed.
Clinical trial ClinicalTrials.gov, NCT02216279
Keywords Molecular imaging . Adrenomedullin .
Pulmonary hypertension . Pulmonary embolism . Nuclear
medicine . Peptide
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Introduction
Pulmonary hypertension (PH) results from a progressive loss
of lung perfusion. Invasive measurement of pulmonary pres-
sure by right heart catheterization is required for precise diag-
nosis and classification of PH. Further non-invasive evalua-
tion of the biology of lung vasculature and of its alterations in
lung vascular disease is currently not available. In the current
phase II study, we evaluated the safety and potential of a
pulmonary vascular endothelial cell tracer for the detection
of pulmonary vascular disease by SPECT imaging.
Adrenomedullin (AM) is a peptide with vasodilatory, anti-
inflammatory and anti-proliferative actions [1]. Specific AM
receptors are present in the pulmonary vascular endothelium
with dense expression in capillaries [2, 3]. The lungs are a
major site for circulating AM clearance [4] and pulmonary
clearance of AM is reduced in animal models of pulmonary
arterial hypertension (PAH) with reduced AM receptor ex-
pression [5–7]. Based on these premises, we developed AM
derivatives that can be labeled with 99mTc for molecular
SPECT imaging of the pulmonary circulation [7]. The lead
derivative is called PulmoBind. PulmoBind binds with excel-
lent affinity to the human AM receptor but lacks the hypoten-
sive effects of native adrenomedullin [7]. 99mTc-PulmoBind is
effective to detect reduced lung perfusion in the monocrota-
line and hypoxia-Sugen models of PAH [6, 7]. In a phase I
trial (study PB-01, ClinicalTrials.gov NCT01539889) of
healthy human subjects, PulmoBind was safe and resulted in
excellent quality SPECT imaging of the lungs [8]. In the cur-
rent phase II study, we aimed to determine the safety and
establish the proof of principle for the use of PulmoBind in
the diagnosis of human pulmonary vascular disease.
Material and methods
The trial was registered at ClinicalTrials.gov (NCT02216279)
and conducted in accordance with the amended declaration of
Helsinki. All participants signed a written informed consent
form. Study subjects were recruited from 3 PH centers: The
Montreal Heart Institute, the Jewish General Hospital and the
Institut Universitaire de Cardiologie et de Pneumologie de
Québec.
The primary safety objectives of the study were to deter-
mine the safety of PulmoBind in PH and to determine the
absence of allergic reaction after a repeated exposure 1 month
later in healthy controls. The primary efficacy objective was to
determine the capacity of PulmoBind lungs scan for detecting
abnormal pulmonary circulation associated with PH.
Control non-smoking participants (n = 15) with no evi-
dence of lung disease were recruited after screening tests to
rule out PH or any lung disorder (history, physical exam,
cardiac ultrasound, chest X-ray and lung function testing)
and any significant kidney or liver disease (history, exam,
biochemistry). Participants with PH (n = 30) were recruited
if they had a diagnosis of PAH (idiopathic, heritable, or sclero-
derma spectrum of disease) or of unoperated chronic throm-
boembolic PH (CTEPH) inWHO functional class II-III with a
6-min walking distance test of ≥250 m. Diagnosis of PH had
to be documented by right heart catheterization performed at
any time prior to screening showing a mean pulmonary arte-
rial pressure (mean PAP) >25 mmHg and a pulmonary vascu-
lar resistance (PVR) >240 dyn/s · cm with a pulmonary capil-
lary wedge pressure or left ventricular end diastolic pressure
≤15 mmHg. Subjects were excluded if they had significant
restrictive lung disease on lung function testing or more than
minimal fibrosis on high resolution computed tomography of
the chest.
PulmoBind drug substance (American Peptide Company,
CA, USA) and diagnostic kits (KABS, St-Hubert, Canada)
were produced according to good manufacturing practices
with drug substance purity >98%. Each labeling kit contained
18.5 μg (4.33 nmol) of PulmoBind drug substance. After la-
beling with 99mTc, radiochemical purity was verified by in-
stant thin layer chromatography before each injection. With
the subjects lying supine, 15 mCi of 99mTc-PulmoBind was
injected in a forearm vein over 5 to 10 seconds. Serial vital
signs (heart rate, blood pressure, respiratory rate, temperature
and oxygen saturation)were recorded at baseline (about 10mi-
nutes before injection) and at 5 min, 10 min, 15 min, 30 min,
and 1 h after PulmoBind injection. Any adverse reaction dur-
ing the imaging study and up to 30 days after was recorded.
The 15 healthy participants underwent a second imaging pro-
cedure with 99mTc-PulmoBind 1 month later.
SPECT-CT image acquisition protocol
Prior to injection, a low dose CTwas performed with subjects
breathing normally to acquire a thoracic attenuation map.
Starting at the time of 99mTc-PulmoBind injection, a 35 min
planar dynamic anterior and posterior acquisitions of the lungs
were performed with the nuclear camera followed by a 20min
SPECT acquisition. Static planar imaging was again per-
formed after 60min. The injection syringe was counted before
and after injection to determine the exact quantity of drug
product administered.
Image analysis
Image analysis was performed at the Montreal Heart
Institute nuclear medicine core lab. Both qualitative and
semi-quantitative analyses were performed. For the qual-
itative analysis, all scans were blindly read by a nuclear
medicine specialist (FH) and quoted according to a pre-
determined scoring grid to describe the presence of seg-
mental perfusion defects suggestive of pulmonary
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embolism and for severity as well as extent of heteroge-
neity of distribution of Pulmobind. The right and left
lungs were scored separately. Pulmonary embolism diag-
nosis was made in the presence of ≥ 2 segmental defects
that were pleural-based and triangular-shaped. Perfusion
abnormalities not respecting these criteria were consid-
ered heterogeneous. Areas of heterogeneity were graded
for intensity (mild, moderate, or severe) based on apparent
activity, and for their extent of the lung field as mild
(<20% of lung), moderate (20% to 60%), and severe
(>60%). For the semi-quantitative analysis, tomographic
datasets were reconstructed using 3D OSEM (ordered
subset expectation maximization) iterative reconstruction
algorithm with 3D Gaussian filtering for noise reduction.
Semi-automatic 3D regions of interest (ROIs) of the right
and left lungs were drawn using ITK-snap 2.2.0 and ana-
lyzed using in-house software designed with MATLAB
2013a (Mathworks, Natick, MA, USA). The activity dis-
tribution index, a parameter indicative of the distribution
of activity intensity that is independent of spatial distribu-
tion, was developed to obtain a quantification of the ob-
served heterogeneity. To do so, a frequency histogram of
activity intensity per voxel throughout the ROI of each
lung was constructed. Voxels were grouped based on their
intensity in 15 consecutive clusters from 0% (no activity)
to 100% (maximum pixel activity in the ROI), each clus-
ter representing a 6.67% increased activity step. A graph
representing the frequency of voxels (equivalent to the
percentage of lung volume) was then plotted as a function
of the 15 intensity clusters. A reference intensity distribu-
tion was constructed from the data obtained in the 15
healthy control subjects. For each participating subject,
the intensity distribution was then compared to the normal
reference and the percent lung volume with different dis-
tribution was determined and defined as the Bactivity dis-
tribution index^. The activity distribution index was mea-
sured for the right and left lungs and the maximal value
for each subject was analysed.
Table 1 Clinical parameters at
baseline Healthy controls (n = 15) Pulmonary hypertension (n = 30) p value
Age (years) 39 ± 15 54 ± 12 0.0011
Male 10 (66.6%) 9 (30%) 0.0189
Weight (kg) 72 ± 16 70 ± 12 0.6772
Height (cm) 172 ± 10 164 ± 8 0.0063
Body surface area (m2) 1.85 ± 0.25 1.79 ± 0.17 0.3154
PH
Group I, PAH (n) 23
Group IV, CTEPH (n) 7
WHO functional class (II/III) 26/4
6 MWD (m) 473 ± 75
*FEV1 (L) 3.56 (3.36, 4.26) 2.15 (1.85, 2.78) <0.0001
*FVC (L) 4.40 (4.04, 4.95) 2.99 (2.47, 3.85) <0.0001
Echocardiography
PA systolic (mmHg) 25 ± 4 71 ± 24 <0.0001
TAPSE (mm) 26.0 ± 3.6 20.4 ± 3.8 <0.0001
RVMPI 0.21 ± 0.09 0.57 ± 0.30 <0.0001
Hemodynamic
Mean PA pressure (mmHg) 46 ± 12
PVR (Wood units) 7.2 ± 4.0
Right atrial pressure (mmHg) 7.8 ± 4.4
Cardiac output (L/min) 5.1 ± 1.2
*eGFR (ml/min/1.73 m2) 96 (90, 111) 80 (73, 89) 0.0008
*NT-proBNP (ng/L) 29 (11, 56) 141 (78, 532) <0.0001
Values are mean ± sd , median (Q1, Q3) or n (%)
PH pulmonary hypertension; PAH pulmonary arterial hypertension; CTEPH chronic thromboembolic pulmonary
hypertension; WHO World Health Organization; 6 MWD 6-min walking distance; FEV1 forced expiratory
volume in 1 s; FVC forced vital capacity; PA pulmonary artery; TAPSE tricuspid annulus plane systolic excur-
sion; RVMPI right ventricular myocardial performance index; PVR pulmonary vascular resistance; eGFR esti-
mated glomerulare filtration rate; NT-proBNP N-terminal pro-brain natriuretic peptide.
* p-value based on log-transformed data
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Statistical analysis
Clinical parameters at baseline were presented with descrip-
tive statistics, and both groups (PH vs. healthy) were com-
pared using Student t-tests. Safety parameters at Day 1 were
presented with descriptive statistics at each time of measure-
ment namely: pre-injection and post-injections (5 min,
10 min, 15 min, 30 min, and 60 min). Maximum variation
in each vital sign parameter from the pre-injection value to
post-injection values (ex. maximum drop in systolic/diastolic
blood pressure, maximum increase in heart rate, etc.) was
presented along with the 95% confidence interval for the
mean, in healthy and PH participants. Clinical parameters
and semi-quantitative parameters of PulmoBind lung uptake
at Day 1 were also compared between groups using Student t-
tests. Normality of all parameters was tested and log transfor-
mation was performed wherever needed. Median, lower, and
upper quartiles were presented as appropriate.
Univariate linear regressions were generated in PH subjects
with the heterogeneity distribution index as the dependent
variable and the following parameters of the severity of PH
as the independent variables: type of PH (categorical), 6-min
walk distance, WHO functional class (categorical), cardiac
ultrasound parameters (pulmonary artery systolic pressure,
TAPSE, RVMPI), hemodynamics (mean PAP, PVR, RAP,
cardiac output), and NT-proBNP.
Any adverse event was reported and coded by system or-
gan class and body system according to the MedDRA dictio-
nary (version 17.0).
Statistical analyses were conducted at the Montreal Health
Innovations Coordinating Center using SAS Version 9.4, after
100% on-site clinical monitoring of the case report forms. All
statistical tests were two-sided and performed at a significance
level of 0.05.
Results
The clinical characteristics of healthy controls (n = 15) and PH
subjects (n = 30) are presented in Table 1. There were 23 sub-



























































































































































































































































































































































































































































































































































Peak uptake (%) 63 ± 5 60 ± 12
Time to peak uptake
(min)
4.3 ± 0.8 5.1 ± 1.1*
Uptake at 30 min (%) 49 ± 5 50 ± 11
Lung half-life (min) 71.1 ± 7.8 70.0 ± 11.8
*p <0.05 PH vs. Healthy controls
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scleroderma spectrum of disease) and seven subjects with
CTEPH. Most were in WHO functional class II (n = 26) with
a mean echocardiographic PA systolic pressure of 71 ±
24 mmHg. PH patients were treated with endothelin receptor
antagonists (36.7%), phophodiesterase type-5 inhibitors
(20.0%), riociguat (26.7%), calcium channel blockers
(13.3%), treprostinil (6.7%), and epoprostenol (16.7%). The
mean delay between initial PAH diagnosis and inclusion into
the trial was 5.0 ± 4.7 years.
All subjects completed the study and there were no serious
adverse events. The overall mean labeling efficiency of 99mTc-
PulmoBind at Day 1 was 98% ± 2%. The mean activity of
99mTc-PulmoBind injected was 14.6 ± 1.82 mCi. This repre-
sents a mean amount of PulmoBind drug substance per injec-
tion of 6.78 μg (1.59 nmole). There was one mild adverse
event possibly related to study drug, as 1 PH participant re-
ported a transient sensation of metallic taste following
PulmoBind injection. In two participants (one healthy and
one PH), there was infiltration of PulmoBind in forearm tis-
sues during injection. These subjects were observed and no
local reaction occurred. They were both re-injected (one on
same day and one the day after) without any adverse event.
Serial vital signs at baseline and at each time point following
injection of PulmoBind are presented in Table 2 together with
the mean maximum variations, irrespective of the time point.
There was a mild decrease of systolic and diastolic blood
pressures over the first 15 min that remained stable for the
duration of the study (1 h). There was no clinically significant
change in heart rate, respiratory rate, temperature, and oxygen
saturation.
Peak PulmoBind uptake by the lungs was 63% ± 5% of the
injected dose in healthy controls and was similar in PH sub-
jects although with greater variability at 60% ± 12% (Table 3).
Uptake at 30 min and lung half-life of PulmoBind were also
not statistically different. The time to peak lung uptake was
however longer in the PH group (5.1 ± 1.1 min) compared to
the healthy controls (4.3 ± 0.8 min, p = 0.0194). Blinded qual-
itative analysis of PulmoBind lung scans resulted in the iden-
tification of segmental perfusion defects compatible with pul-
monary embolism in nine PH subjects, but in none of the
healthy controls. For CTEPH subjects, 7/7 were interpreted
as having segmental perfusion defects compatible with pul-
monary embolism, and for PAH it was 2/23 subjects. A sub-
ject with CTEPH is shown in Fig. 1 compared to the MAA
lung scan obtained previously (5 years before) in the same
subject and to a healthy control. In that subject and despite
Fig. 1 99mTc-PulmoBind lung
scan in CTEPH. 99mTc-
PulmoBind lung scans in a
healthy control (a) and in a
subject with CTEPH (b)
compared to the MAA lung scan
of the same CTEPH subject
5 years earlier (c)
Table 4 Qualitative evaluation of
lung PulmoBind uptake at Day 1 Healthy controls (n = 15) right left PH (n = 30) right left
Heterogeneity present (n (%)) 5 (33.3%) 3 (20.0%) 14 (46.7%) 15 (50.0%)
Severity (n)
Mild 5 3 6 6
Moderate 0 0 7 8
Severe 0 0 1 1
Extent (n)
Mild 2 1 0 1
Moderate 3 2 10 10
Severe 0 0 4 4
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the long delay between exams, MAA and PulmoBind detect
multiple segmental perfusion defects of similar sizes and
distribution.
There was mild heterogeneity of distribution of
PulmoBind, mostly of mild extent, in about 30% of healthy
control lungs (Table 4). None of the healthy controls demon-
strated more than mild heterogeneity. Moderate to severe het-
erogeneity of moderate to severe extent was present in about
50% of subjects with PH and was unevenly distributed be-
tween the right and left lungs (Table 4). Examples of abnormal
PulmoBind lung scans in subjects with PAH are shown in
Fig. 2. Examples of exams in various types of PH are shown
in Fig. 3 and in a video (online supplemental material).
Compared to the healthy controls, areas of prominently re-
duced activity are evident in both lungs. The deficits are het-
erogeneously distributed within one lung and between the
right and left lungs with some areas that are apparently spared
showing normal or even increased activity. No specific pat-
terns of distribution were found with variations between sub-
jects. Interestingly, in the only subject with vasodilator-
responsive PAH that was included into the study, a completely
normal distribution of PulmoBind was found (bottom scan of
Fig. 2).
We developed the activity distribution index; a semi-
quantitative parameter indicative of the heterogeneity of
PulmoBind lung activity for each individual compared to a
reference distribution derived from our healthy control popu-
lation. The activity distribution index in healthy controls was
41% ± 13% (Fig. 4). The value was higher in all PH subjects at
65% ± 28% (p = 0.0003), as well as in the PAH only subjects
at 62% ± 27% (p = 0.0037). The frequency histogram of lung
voxels intensity from which the activity distribution index is
computed is shown in Fig. 5 for healthy controls at day 1 and
day 30 as well as for PH subjects. In controls, the activity is
distributed following a standard bell curve with excellent re-
producibility of results after a repeated exam. In PH subjects,
the activity distribution is skewed to lower intensity voxels.
The activity distribution index was not correlated with param-
eters of PH severity.
Discussion
There is currently no imaging test that can provide direct in-
formation on the biologic properties of the pulmonary vascu-
lar endothelium [9]. It is generally recognized that endothelial
dysfunction is an initiating and/or perpetuating event in pul-
monary vascular diseases [10]. Pulmonary vascular diseases
can lead to PH, a devastating condition often diagnosed late in
the evolution process, as a substantial proportion of the pul-
monary vascular bed must be affected before an elevation of
pulmonary pressures is clinically detectable at rest. We devel-
oped PulmoBind, an AM receptor ligand, for the diagnosis of
Fig. 2 99mTc-PulmoBind lung scan in PAH. 99mTc-PulmoBind lung
SPECT in a control subject (a), in three subjects with PAH (b,c,d) and
in one subject with idiopathic reversible PAH (e)
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pulmonary vascular disease [5, 7, 8, 11, 12]. PulmoBind spe-
cifically binds to the human AM receptor that is densely
expressed in the pulmonary vascular endothelium, mostly in
capillaries [2, 3]. The pulmonary circulation is the primary site
for circulating AM clearance [4, 12]. The level of expression
and activity of the AM receptor will therefore modify
PulmoBind uptake by the lungs. In this phase II human study,
we evaluated the safety of PulmoBind administration in sub-
jects with PH and its capacity to detect changes in the pulmo-
nary circulation associated with PH.
In a previous phase I trial in 20 healthy subjects, we dem-
onstrated that 99mTc-PulmoBind was safe and well tolerated
and resulted in lung imaging of excellent quality [8].
Similarly, 99mTc-PulmoBind injections did not cause any se-
rious adverse events in the 15 healthy controls and 30 PH
subjects included in the current study. In two subjects, there
was accidental local infiltration in forearm tissues with no
local reaction. There were no clinically significant variations
of vital signs. Compared to baseline, a mild decrease in sys-
temic blood pressure was observed in the first 15 min after
injection that was maintained for the duration of the study
(1 h). This decrease is compatible with the normal physiolog-
ical variation expected during the experimental procedure: the
subjects were comfortably lying supine in a quiet environment
and baseline measurements were obtained about 10 min prior
to PulmoBind injection. There is indeed a normal decrease in
systemic blood pressure measurement that stabilizes after
15 min of rest in seated or supine subjects [13, 14]. The mean
lung scan dose of PulmoBind in humans is of 6.78 μg, an
amount with a safety margin of at least 100X in animal studies
compared to native AM [7]. Furthermore, repeated injection
of 99mTc-PulmoBind in the healthy controls did not cause any
adverse reaction.
The efficacy analysis included a blinded qualitative evalu-
ation as well as semi-quantitative analysis of 99mTc-
PulmoBind lung SPECT. Segmental perfusion defects com-
patible with CTEPH were found in 7/7 subjects with CTEPH
and in 2/23 subjects with PAH. Although limited to perfusion
imaging without simultaneous lung ventilation studies, this
suggests that 99mTc-PulmoBind SPECT imaging could be fur-
ther tested for the diagnosis of CTEPH in subjects with PH.
This finding also provides impetus to evaluate PulmoBind for
the diagnosis of acute pulmonary thrombo-embolic disease
with direct comparison to labeled MAA and angio-CT.
About 50% of PH subjects had moderate to severe lung
heterogeneity of moderate to severe extent while controls
had no more than mild heterogeneity. No specific patterns of
heterogeneity could be discerned as the distribution varied
within each lung and between the right and left lungs. The
abnormal distribution patterns also varied between individuals
(Fig. 2). These data, obtained in WHO functional class II PH,
are consistent with histologic studies from advanced PH trans-
plant candidates demonstrating that the pathologic processes
in PH are not homogeneously distributed [15]. We found that
some regions demonstrated absent or reduced uptake of
99mTc-PulmoBind while others had normal or even seemed
to have increased uptake explaining that the overall mean lung
uptake was similar to healthy controls, although with much
wider variability. While it is certain that non-perfused regions
will have no uptake, as confirmed in the CTEPH subjects, we
Fig. 3 99mTc-PulmoBind lung scan in various types of PH. 99mTc-PulmoBind lung SPECT in a control subject and in subjects with CTEPH, heritable
PAH and idiopathic PAH. Also available online as a supplemental video
Fig. 4 Activity distribution index. The activity distribution index, a
parameter indicative of heterogeneity of lung 99mTc-PulmoBind
distribution is shown in healthy controls (n = 15), in all PH subjects of
the trial (n = 30) and in the PAH subgroup only (n = 23). Values are mean
with 95% confidence intervals
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cannot exclude that some perfused regions with endothelial
dysfunction may have no or reduced AM receptor expression
leading to reduced activity. Moreover, because 99mTc-
PulmoBind is a very small molecular tracer, it probably can
detect small areas of non-perfused lung associated to the
microthrombi observed in PAH [15]. Conversely, increased
expression of AM receptors in non-affected lung regions
could account for apparent increase in uptake. Although spec-
ulative, some lung regions may indeed compensate by
recruiting vasculature and increasing the expression of the
AM receptor. Temporal evaluation of these processes in vari-
ous types of PH could provide novel pathophysiologic in-
sights. Also remarkable is the normal perfusion pattern in
our vasodilator-responsive idiopathic PAH patient. This type
of patient represents a rare instance of idiopathic PAH where
hemodynamics can normalize with therapy, and the normal
perfusion we found is consistent with this phenotype.
To semi-quantitatively evaluate the distribution of 99mTc-
PulmoBind, we developed the activity distribution index. An
increase in the index is indicative of heterogeneity of distribu-
tion compared to the mean of healthy controls. The activity
distribution index was markedly increased in all PH subjects
as well as in the PAH subgroup only. Although this study is
limited in size with mostly WHO class II subjects, we ex-
plored potential correlation of the activity distribution index
with parameters of severity of PH and found no correlation.
Larger sample size studies will be required to determine if this
parameter could be a useful biomarker of disease severity and
potentially of response to therapy. We found that the time to
peak lung uptake of PulmoBind was significantly increased in
PH subjects. This could be related to longer pulmonary transit
times associated with lower cardiac outputs in these subjects.
We cannot, however, exclude that this difference could be
caused by other non-pathologic factors since the controls
and PH subjects had different demographics with more wom-
en and older subjects in the PH group. This Bproof of concept^
and safety phase II study has several inherent limitations, in
particular its small sample size, the variable time since PH
diagnosis and the lack of a comparison to a perfusion agent.
Larger studies including more subtypes of PH will be neces-
sary to determine if specific patterns of distribution could be
indicative of specific etiologies. Direct comparative studies to
labeled MAA and angio-CT are required to determine if
PulmoBind provides any additional advantage to these agents.
The major strength of this study are that it demonstrates for
the first time that we can safely image human pulmonary
vascular disease by using a vascular endothelial cell tracer.
Other molecular tracers were previously used to image the
pulmonary circulation and were recently reviewed in detail
[9]. Many of these tracers also targeted properties of the pul-
monary vascular endothelium, but none have been further
developed for clinical use despite some encouraging results.
Conclusion
In this phase II study, molecular SPECT imaging of the pul-
monary vascular endothelium using 99mTc-PulmoBind was
Fig. 5 Frequency distribution of
lung 99mTc-PulmoBind activity.
The percentage of lung volume
per voxel intensity is plotted for
PH subjects and controls (a) and
for controls on day 1 and day 30
(b) for the right and left lungs.
Values are mean with 95%
confidence intervals
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safe. PulmoBind showed potential to detect both pulmonary
embolism and abnormalities indicative of pulmonary vascular
disease in PAH. However, it is unclear whether PulmoBind is
a perfusion tracer only or if it adds functional information on
adrenomedullin receptors in PH. The potential clinical utility
of this agent should now be tested in phase III trials with direct
comparison to labeled MAA and angio-CT.
AM, adrenomedullin; CT, computed tomography; CTEPH,
chronic thromboembolic pulmonary hypertension; MAA,
macroaggregates of albumin; PA, pulmonary artery; PAH,
pulmonary arterial hypertension; PH, pulmonary hyperten-
sion; ROI, region of interest; SPECT, single photon emission
computed tomography; Tc, technetium
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